Related Experiment Video

Updated: Jun 7, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models

Rute B Marques1, Natasja F Dits, Sigrun Erkens-Schulze

  • 1Department of Urology, Josephine Nefkens Institute, Erasmus Medical Center, Rotterdam, The Netherlands.

Plos One
|October 27, 2010
PubMed
Abstract

Insights

Prostate cancer therapy resistance may stem from androgen receptor pathway changes or alternative survival strategies. TWIST1, VAV3, and DKK3 are identified as key genes in overcoming androgen dependence, offering potential therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer initially relies on androgens, making hormonal therapy a primary treatment for advanced stages.
  • Despite initial success, prostate cancer frequently recurs, developing resistance to androgen deprivation.
  • Understanding the mechanisms of therapy resistance is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the molecular mechanisms by which androgen-dependent prostate cancer cells survive and grow under androgen-deprived conditions.
  • To identify genetic differences between androgen-responsive and therapy-resistant prostate cancer cell lines.
  • To explore potential biomarkers and therapeutic targets for overcoming treatment resistance.

Main Methods:

  • Utilized microarray technology to compare gene expression profiles between androgen-responsive (PC346C) and therapy-resistant (PC346DCC, PC346Flu1, PC346Flu2) prostate cancer cell lines.
  • Performed pathway analysis to identify enriched biological functions and disease associations.
  • Validated key gene expression changes (TWIST1, VAV3, DKK3) in patient samples.

Main Results:

  • Identified 487 differentially expressed transcripts between responsive and resistant cell lines, with most common across resistant sublines.
  • Observed up-regulation of oncogenes TWIST1 and VAV3, and down-regulation of tumor suppressor DKK3 in therapy-resistant cells, suggesting an androgen receptor (AR) bypass mechanism.
  • Confirmed deregulation of TWIST1, VAV3, and DKK3 in patient samples, correlating with prostate cancer progression.

Conclusions:

  • Therapy resistance in prostate cancer can arise from adaptations within the AR pathway or via alternative survival mechanisms.
  • TWIST1, VAV3, and DKK3 are identified as significant players in bypassing the AR pathway, contributing to androgen-independence.
  • These genes represent promising candidates for novel therapeutic targets and biomarkers for prostate cancer treatment resistance.

More Related Videos

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...